In our series, the frequencies of observing patients with CMV-Ag, CMV treatment, and CMV infection symptoms were 33.7% (69/205), 9.3% (19/205), and 2.9% (6/205) in the period ≥1 year post transplantation, respectively. This evidence concerns the gene RENBP and cytomegalovirus infection.